

March 13, 2026

Company name: Pharma Foods International Co., Ltd.
 Representative: Mujo Kim, President
 (Securities code: 2929 Prime Market)
 Inquiries: Seiyu Harada, General Manager of
 Corporate Strategy Department
 (Telephone: +81-75-394-8600)

Notice Regarding Revision of Full-Year Financial Results Forecast for the Fiscal Year Ending July 2026

Pharma Foods International Co., Ltd. (the “Company”) hereby announces that, reflecting a comprehensive analysis of its current performance dynamics, the Company has revised the consolidated full-year financial results forecast for the fiscal year ending July 31, 2026 (August 1, 2025 to July 31, 2026), which was originally announced on September 11, 2025, as set forth below.

1. Revision of Consolidated Results Forecast for the Fiscal Year Ending July 2026

	Net Sales	Operating Profit	Ordinary Profit	Net Income Attributable to Owners of the Parent	Earnings per Share
	JPY (M)	JPY (M)	JPY (M)	JPY (M)	JPY
Previous Forecasts (A)	68,000	1,500	1,500	1,000	34.64
Revised Forecasts (B)	67,000	2,000	2,000	1,500	51.65
Change (B-A)	▲1,000	500	500	500	—
Change (%)	▲1.5%	33.3%	33.3%	50.0%	—
(Reference) Actual Consolidated Results for the Previous Fiscal Year ended July 31, 2024	65,260	2,367	2,553	368	12.83

2. Reasons for the Revision

Under the company’s medium-term management plan “New Value Creation: 1K Project,” the Company has strategically advanced its commitment to delivering transformative value through intensive R&D in the healthcare sector, while concurrently optimizing profitability and operational efficiency.

During the second quarter (interim period), the Company’s B2C business maintained strong sales momentum in its flagship “Newmo Series.” This was further bolstered by the accelerated growth of new products, including “LACTORON Tablets,” “TENRAI SEIRYU Tablets,” and “HEALTH PAN C Tablets 2000,” which are progressively establishing themselves as key profit drivers alongside our core brands. Furthermore, through a Group-wide prioritization of capital efficiency and optimized profitability, the Company now projects that earnings will exceed its previous guidance.

For the remainder of the full fiscal year, the Company remains steadfast in our mission to pioneer new value and further enhance profitability. By fortifying our financial foundation, the Company is committed to driving sustainable growth and maximizing long-term corporate value across the Pharma Foods group.